YKL-40 predicts poor prognosis for bladder cancer
As reported in Urologic Oncology, the gene expression and serum level of YKL-40 are higher in patients with bladder cancer than healthy controls. Serum YKL-40 levels predict poor prognosis in patients with muscle-invasive bladder cancer (HR=1.75).
Cisplatin monotherapy effective in pediatric high-risk hepatoblastoma
As reported in the Journal of Pediatric Hematology/Oncology, treatment of children with high-risk hepatoblastoma (n=14) with cisplatin monotherapy was as effective as cisplatin + doxorubicin combination therapy, but with less toxicity. The complete resection rate was 78.6%, the event-free survival rate was 81.8%, and the OS rate was 100%.
Loss of PTEN expression portends poor prognosis in IPMNs of the pancreas
As reported in Clinical Cancer Research, loss of PTEN in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas (n=36) is associated with invasiveness and poor survival.